ARID1A and neoplasm: Moreover, clinicopathological analyses revealed that ARID1A protein loss or reduced expression occurs in 77% of CRC patients [6, 9], and is associated with the advanced tumor-node-metastasis (TNM) stage, suggesting that ARID1A is a key tumor suppressor in CRC and its loss is strongly linked to CRC progression and metastasis.